Your browser doesn't support javascript.
loading
Protective effect of Pterospermum rubiginosum bark extract on bone mineral density and bone remodelling in estrogen deficient ovariectomized Sprague-Dawley (SD) rats.
Anish, Rajamohanan Jalaja; Mohanan, Biji; Nair, Aswathy; Radhakrishnan, K V; Rauf, Arun A.
Affiliation
  • Anish RJ; Department of Biochemistry, University of Kerala, Kariavattom Campus, Thiruvananthapuram, 695581 India.
  • Mohanan B; Chemical Sciences and Technology Division CSIR-National Institute for Interdisciplinary Science and Technology (CSIR-NIIST), Thiruvananthapuram, 695019 India.
  • Nair A; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002 India.
  • Radhakrishnan KV; Department of Biochemistry, University of Kerala, Kariavattom Campus, Thiruvananthapuram, 695581 India.
  • Rauf AA; Kerala State Palmyrah Products Development and Workers' Welfare Corporation Limited, Trivandrum, 695122 India.
3 Biotech ; 14(4): 101, 2024 Apr.
Article de En | MEDLINE | ID: mdl-38464615
ABSTRACT
Osteoporosis is a common metabolic old age disorder characterised by low bone mass content (BMC) and mineral density (BMD) with micro-architectural deterioration of the extracellular matrix, further increasing bone fragility risk. Several traditional remedies, including plant extracts and herbal formulations, are used worldwide by local healers to improve the overall bone health and metabolism as an excellent osteoregenerative agent. Pteropsermum rubiginosum is an underexplored medicinal plant used by tribal peoples of Western Ghats, India, to treat bone fractures and associated inflammation. The proposed study evaluates the elemental profiling and phytochemical characterisation of P. rubiginosum methanolic bark extract (PRME), along with detailed In vitro and In vivo biological investigation in MG-63 cells and Sprague-Dawley (SD) rats. AAS and ICP-MS analysis showed the presence of calcium, phosphorus, and magnesium and exceptional levels of strontium, chromium, and zinc in PRME. The NMR characterisation revealed the presence of vanillic acid, Ergost-4-ene-3-one and catechin. The molecular docking studies revealed the target pockets of isolated compounds and various marker proteins in the bone remodelling cycle. In vitro studies showed a significant hike in ALP and calcium content, along with upregulated mRNA expression of the ALP and COL1, which confirmed the osteoinductive activity of PRME in human osteoblast-like MG-63 cells. The in vivo evaluation in ovariectomised (OVX) rats showed remarkable recovery in ALP, collagen and osteocalcin protein after 3 months of PRME treatment. DEXA scanning reports in OVX rats supported the above in vitro and in vivo results, significantly enhancing the BMD and BMC. The results suggest that PRME can induce osteogenic activity and enhance bone formation with an excellent osteoprotective effect against bone loss in OVX animals due to estrogen deficiency. Supplementary Information The online version contains supplementary material available at 10.1007/s13205-024-03942-7.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: 3 Biotech Année: 2024 Type de document: Article Pays de publication: Allemagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: 3 Biotech Année: 2024 Type de document: Article Pays de publication: Allemagne